Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001603 · ClinicalTrials.gov registry record

The Effects of Upper Airway and Digestive Tract Tumors on the Immune System

A clinical trial, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

Completed
Registry status
93
Enrollment target

NCT00001603: Completed study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

NCT00001603 is a clinical trial that has completed, run by National Institute on Deafness and Other Communication Disorders (NIDCD). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001603 has completed, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

COMPLETED
Registry status
93 participants
Enrollment target

Study Summary

The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage. Previous studies have shown that tumors of the vocal tract produce signals that could help the tumor escape the body's immune defenses and use the body's energy and mineral stores to grow. Researchers are hoping to learn more about what signals give tumor cells an advantage to live and grow, how tumor cells control these signals, and how these signals affect the rest of the body. This study will look closer at researchers belief that tumors in the vocal tract contain genes (genetic information) that abnormally function to allow the tumors to survive and grow against the attack of the body's normal immune system Patients with cancerous tumors (squamous cell carcinoma) and benign (non-cancerous) tumors (papilloma) of the upper aerodigestive tract who are candidates for standard or investigational therapy are eligible to participate in this study. Tumor cells will be collected from patients participating in the study, who will undergo standard surgical treatment or biopsies for their conditions. Once tumor cells are collected they can be analyzed for their genetic make-up. In addition, patients will undergo several tests using skin, blood, and urine to look closely at the function of their immune systems and metabolism.

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 1996-12
Est. Completion 2004-12

What the finished NCT00001603 record still lists

NCT00001603 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00001603 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00001603 about?

NCT00001603 is a clinical study titled "The Effects of Upper Airway and Digestive Tract Tumors on the Immune System". The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage. Previous studies have shown that tumors of the vocal tract produce signals that could help the tumor escape the body's...

What is the current status of trial NCT00001603?

This trial is currently completed. The enrollment target is 93 participants. The study started on 1996-12. Estimated completion is 2004-12.

Who is sponsoring clinical trial NCT00001603?

This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00001603, the US trial registry maintained by the National Library of Medicine. NCT00001603 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.